Background and objective: Patients with chronic obstructive pulmonary disease (COPD) and chronic hypercapnic respiratory failure (CHRF) characteristically have exercise intolerance and limitations in performing conventional training. Therefore, the aim of this study was to investigate the acute effects of noninvasive ventilation (NIV) as a supportive tool during exercise in CHRF. Methods: Two cycle endurance tests (CET) at 60% of the peak work rate were performed. Patients were randomly assigned to cycle in two conditions: (i) high-pressure NIV (mean inspiratory positive airway pressure: 27 AE 3 cm H 2 O) along with oxygen supplementation or (ii) control: oxygen-use only. Transcutaneously measured partial pressure of carbon dioxide (TcPCO 2 ), oxygen saturation and heart rate were continuously recorded. Muscle oxygen availability of intercostal and vastus lateralis muscle was measured during exercise by near-infrared spectroscopy (NIRS). Results: A total of 20 patients with CHRF (forced expiratory volume in 1 s (FEV 1 ): 19 AE 4% predicted, partial pressure of oxygen (PaO 2 ): 55 AE 9 mm Hg, partial pressure of carbon dioxide (PaCO 2 ): 51 AE 7 mm Hg) were recruited in a randomized cross-over trial. On NIV, COPD patients increased cycle endurance time by 39% compared to oxygen-use only (663 AE 360 vs 477 AE 249 s, P = 0.013). On NIV, TcPCO 2 was significantly lower at rest (44.9 AE 6.2 vs 50.7 AE 6.6 mm Hg, P < 0.001) and at isotime (50.0 AE 5.5 vs 56.1 AE 6.2 mm Hg, P < 0.001). Oxygen availability in the intercostal
SUMMARY AT A GLANCE
Non-invasive ventilation (NIV) with a high inspiratory pressure significantly improved cycle endurance time, reduced exercise-induced hypercapnia and relieved exertional dyspnoea in chronic obstructive pulmonary disease (COPD) patients with chronic hypercapnic respiratory failure. Complementary NIV with high inspiratory pressure support during cycling is feasible and a beneficial modality in the most severe COPD patients.
INTRODUCTION
Pulmonary rehabilitation (PR) including exercise training is a cornerstone modality of chronic obstructive pulmonary disease (COPD) management with a level 'A' evidence to improve exercise capacity, dyspnoea and quality of life. 1, 2 Promising evidences have shown that COPD patients with chronic hypercapnic respiratory failure (CHRF) may benefit from PR. 3, 4 However, their severely impaired clinical status and reduced capacity may restrain them in performing conventional exercise training including cycle endurance exercise. A number of studies have investigated the effects of noninvasive ventilation (NIV) as a supplemental tool during exercise with the goal of enabling exercise training at higher intensities not usually feasible for these patients. 5, 6 It is known that NIV assists the function of overburdened and less effective respiratory muscles by reducing the work of breathing (WOB), defined as respiratory muscle unloading, as well as mitigating dyspnoea. 7, 8 Furthermore, an established hypothesis is that NIV may lead to a switch of arterial blood flow from respiratory muscles to leg muscles, thus delaying the onset of limb muscle fatigue in COPD patients during leg exercise. 9, 10 To date, the beneficial effects of NIV during exercise in COPD have mainly been reported by studies including only patients without CHRF or using low-pressure NIV (inspiratory pressure support < 20 cm H 2 O). 7, 11 However, according to the German NIV guidelines, 12 high inspiratory pressure support (≥20 cm H 2 O) is most effective to decrease PCO 2 values in CHRF patients secondary to COPD. 13, 14 Hence, the aim of this study was to investigate the acute effects of high-pressure NIV as an add-on tool during exercise in COPD patients with CHRF. We hypothesized that supplemental oxygen in combination with NIV set at high pressure during cycle exercise in COPD patients with CHRF is superior to oxygen supplementation with respect to exercise capacity, carbon dioxide pressure, dyspnoea and muscle oxygenation indexes.
METHODS

Study design
Patients with very severe COPD referred for an inpatient PR programme at the Schoen Klinik Berchtesgadener Land (Schoenau am Koenigssee, Germany) were screened for eligibility. The study was conducted in accordance with the amended Declaration of Helsinki, was registered at www.clinicaltrials.gov (identification number NCT 02877290) and approved by the Ethics Committee of the Bavarian Physician Association (ID16050). Prior to participation in the study, all subjects gave written, signed, informed consent.
Study population
COPD patients with GOLD (Global Initiative for chronic Obstructive Lung Diseases) stage IV 15 admitted to PR between August 2016 and October 2017 were recruited. Inclusion criteria were: age 40-80 years old, CHRF (PCO 2 > 50 mm Hg at rest or during exercise) 12 and established therapy of nocturnal NIV. Exclusion criteria were: acute exacerbation within the last 4 weeks, diagnosed chronic heart failure or an acute coronary syndrome and any orthopaedic problem limiting patients' ability to cycle.
Intervention
NIV settings
During PR, patients performed one to two practice sessions of cycling with NIV for familiarization with the exercise setting and the NIV support during exercise. NIV was applied using a Stellar 100 device (Resmed, Planegg, Germany) and a full face mask (Quattro Air; Resmed, Planegg, Germany). The assisted pressurecontrolled ventilation (APCV) mode was chosen due to the familiarity of patients with this mode (further information on NIV settings can be found in Appendix S1, Supplementary Information).
CET protocol
Patients performed two cycle endurance tests (CET) at 60% of peak work rate. Cycle endurance time was defined as the primary outcome. CET were conducted in a randomly assigned order from two conditions: (i) NIV condition of a CET with high-pressure NIV and oxygen supplementation and (ii) control condition of a CET with the same amount of oxygen supplementation only applied via nasal prongs (for further information, see Appendix S1 (Supplementary Information)).
Transcutaneously measured partial pressure of carbon dioxide
Beside oxygen saturation and heart rate, transcutaneously measured partial pressure of carbon dioxide (TcPCO 2 ) as surrogate for arterial carbon dioxide partial pressure was also measured continuously with the SenTec Digital Monitoring System (SenTec AG, Therwil, Switzerland) by a sensor connected at the earlobe. 16 Measurements at rest and during exercise were performed under the conditions described above. A comprehensive kinetics of the heart rate was determined by the mean response time (MRT) (for more information, see Appendix S1 and Fig. S4 , Supplementary Information).
Analyses included isotime measurement from the two CET defined as the time point where the shorter test ended (values at baseline, 20%, 40%, 60% and 80% of isotime were added to provide a trend over the testing period). Using isotime ensured that the amount of physical workload performed by the patient during cycling was similar, allowing a reliable comparison between tests with and without NIV.
Muscle oxygen availability
Muscle oxygen availability was measured by nearinfrared spectroscopy (NIRS), a non-invasive technique for evaluating tissue oxygenation. 17 To measure muscle tissue oxygen saturation index (TSI) as a surrogate of oxygen availability, we used the PortaLite NIRS system (Artinis Medical Systems, Elst, the Netherlands). One set of NIRS optodes was placed on the vastus lateralis of the right leg. A second set of NIRS optodes was applied on the seventh intercostal space to measure the intercostal muscle as a representative of respiratory muscles during exercise. 18 More information on NIRS technology is provided in Appendix S1 (Supplementary Information).
Perceived dyspnoea and leg fatigue
Levels of dyspnoea and leg fatigue at rest and at the end of CET were documented by using a modified Borg scale (0-10). 19 
Statistical analysis Sample size calculation
A priori sample size computation using GPower 3.1 (Heinrich-Heine-University, Dusseldorf, Germany) was based on the hypothesis that cycling with NIV will result in a clinically relevant improvement in CET of at least 105 s according to previous findings. 20 Estimating an SD of 120 s, using a power of 95% and an alpha error of 5% (effect size Cohen's d = 0.8), a total of 20 patients were sufficient to achieve the addressed power goal for this effect size.
Randomization and allocation concealment
Tests were randomized by creating 10 sealed envelopes with one order of tests and 10 of the other order. Envelopes were shuffled and one was chosen immediately before testing to ensure the order of test sequences was random.
Blinding
Blinding of researchers and study participants was not possible within the study setting due to the nature of the intervention. However, the statistician (W.H.) who performed data analyses was blinded to group allocation.
Statistical methods
Data were analysed for outliers and for normality. A cross-over design using t-tests was used to analyse continuously distributed data and test for significant differences as well as possible period or carry-over effects.
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95% CI were computed for means as well as for treatment effects, that is the difference of means was computed. The type I error for the cross-over, period and carry-over effect was set to 5%. For ordinary and quasicontinuously distributed data, the Wilcoxon-signed rank test was used. All reported tests were two-sided, and 
RESULTS
A total of 89 patients using nocturnal NIV were screened for the study. Out of these, 20 met the inclusion criteria and were enrolled in the trial (Fig. 1) . All patients enrolled to the study completed both CET and were included in the analysis. Demographic data is shown in Table 1 . All patients had an indication for nocturnal NIV due to their CHRF and used this for 18 AE 27 months before inclusion in the trial. During CET with NIV, patients used individualized inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP) which were on average 27 AE 3 and 6 AE 1 cm H 2 O, respectively. The ventilator breathing frequency was set at 20 AE 3 breaths per minute and was kept constant during exercise with NIV. Inspiration time was 1.0 AE 0.2 s and the mean inspiratory to expiratory ratio was 1 to 2.3 AE 0.2. Oxygen supplementation during both CET was set at a mean flow rate of 3.8 AE 1.6 L/min according to national guidelines to maintain a partial oxygen pressure ≥ 60 mm Hg during exercise (oxygen titration including blood gas analysis was done prior to the study). 24 
Exercise capacity
In NIV condition, COPD patients had an average increase in cycle endurance time of 39% compared to control condition (663 AE 360 vs 477 AE 249 s, P = 0.013) and a between-group difference of 186 s (95% CI: 44-329) (Fig. 2) . Specifically, cycling duration improved in 15 out of 20 patients with NIV. The median increase in dyspnoea sensation on the Borg scale from baseline to the end of CET was significantly lower when cycling with NIV even though patients cycled longer (2 vs 4, P = 0.003) ( Table 2 , Fig. S1 (Supplementary Information)) .
Respiratory and haemodynamic changes
In NIV condition, TcPCO 2 values were significantly lower at rest (44.9 AE 6.2 vs 50.7 AE 6.6 mm Hg, P < 0.001) and at isotime (50.0 AE 5.5 vs 56.1 AE 6.2 mm Hg, P < 0.001) compared to control condition (Fig. 3) . Oxygen saturation was significantly higher with NIV during exercise (Fig. S2, Supplementary Information) . TSI as a surrogate of oxygen availability of intercostal muscles remained stable during cycling with NIV ([Δ] = −0.3% at isotime), whereas it showed a declining trend towards significance ([Δ] = −1.8% at isotime) without NIV (control condition) (between-group difference: 1.5%; 95% CI: −0.37% to 3.29%, P = 0.109; Fig. 4 ). More results can be found in Appendix S2 (Supplementary Information).
Adverse events
All patients tolerated the use of NIV during exercise well and were able to perform cycle training with NIV. Furthermore, no adverse events related to the study intervention were observed.
DISCUSSION
To the best of our knowledge, this is the first study demonstrating beneficial acute effects of high-pressure 6MWD, 6-min walk distance; body cell mass, lean body mass minus extracellular mass; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting β2-agonists; LAMA, long-acting antimuscarinic agents; LTOT, long-term oxygen therapy; NIV, non-invasive ventilation; NT-proBNP, N-terminal prohormone of brain natriuretic peptide (for values below 300 pg/mL, the presence of a heart failure is unlikely according to Maisel et al. 
NIV during exercise in COPD
NIV in COPD patients with CHRF. We found that the use of NIV during a single cycling training session significantly improves exercise tolerance, CO 2 retention and dyspnoea perception. To date, a limited number of studies have investigated the short-and long-term effects of NIV as an add-on to exercise training in COPD. However, most of these studies did not include patients with CHRF. 5, [25] [26] [27] [28] [29] Evidence has shown that patients with advanced COPD but without CHRF are usually able to perform exercise endurance training, which can be a feasible and effective exercise modality without the use of NIV. 30 In CHRF, however, endurance exercise may be a challenge and the beneficial effect of NIV that could facilitate endurance training is often debated.
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Only a few studies with small sample sizes have investigated short- 6, 31 or long-term 32 effects of NIV during exercise including patients with CHRF (range of resting PCO 2 : 50-52 mm Hg). However, all these studies provided only relatively low inspiratory pressure during NIV exercise (IPAP range: 12-17 cm H 2 O). It might be speculated that these low-pressure support values (<20 cm H 2 O) were not high enough to sufficiently unload respiratory muscles. Recent studies have shown that high pressure (≥20 cm H 2 O) is superior in decreasing respiratory muscle activity 33 and thus lowering CO 2 values. 34 Furthermore, it has been shown that nocturnal NIV is better tolerated by patients with severe CHRF and resulted in significant improvements in exercise-related dyspnoea, daytime PCO 2 and quality of life when high pressures are used compared to lowpressure NIV. 35 Up to now, only one study has investigated the use of high-pressure NIV (IPAP: 29 AE 4 cm H 2 O) during walking in CHRF patients and found similar benefits (walking distance: +17%, pCO 2 : −1.8 mm Hg, Borg dyspnoea scale: −2 points) like in the recent study during cycle exercise. 36 However, a direct comparison between the effects of low versus high inspiratory pressure during exercise cannot be made. This should be investigated by future studies using adequate methodology.
In the current study, COPD patients were able to cycle longer with NIV compared to control condition. On average, cycle duration was significantly improved by 186 s exceeding the threshold of minimal important difference (>105 s) reported for COPD patients. 20 Patients cycled longer during NIV condition and simultaneously experienced a lower increase of dyspnoea throughout the CET (Δ Borg scale rating: 2 vs 4 points, P = 0.003). This improvement in dyspnoea on the Borg scale was clinically relevant and can be considered as an important relief of exertional dyspnoea due to the NIV use. 37 Nevertheless, leg fatigue presented a higher increase in NIV condition compared to control (Δ Borg scale rating 4 vs 3, P = 0.001) likely indicating a greater muscular stimulus which is an important trigger of improving exercise performance during long-term training programmes. 38 Furthermore, systolic blood pressure was significantly lower at baseline, exercise and recovery phase compared to control condition (Fig. S3, Supplementary Information) potentially indicating reduced cardiac output during NIV as a consequence to high-intensity pressures. 34 On the other hand, heart rate was significantly higher on NIV at baseline and recovery likely reflecting compensation for a decrease in stroke volume.
In addition, the current study demonstrated that the use of NIV with high pressures during cycling in patients with CHRF leads to a significant reduction in TcPCO 2 .
In the current study, NIV showed a comparable favourable effect with control condition on vastus lateralis oxygen availability which was preserved during cycling. This is also true for the intercostal muscles oxygen availability, even though a declining trend on TSI levels was observed in control condition. The slightly reduced TSI of intercostal muscles, when only oxygen was administered compared to NIV add-on, is not adequate to allow us to make concrete statements about a likely superiority of NIV in maintaining oxygen levels in intercostal muscles (for a more detailed discussion, see Appendix S3 (Supplementary Information)). However, evidence has shown that NIV may improve gas exchange and/or reduce the WOB by counteracting with intrinsic positive end-expiratory pressure (PEEP). 39 NIV reduces pulmonary intrinsic pressure and consequently could have decreasing or delaying the occurrence of dynamic lung hyperinflation. 40 Additionally, at high levels of inspiratory pressure, NIV may consistently increase dynamic lung compliance and tidal volume, and improve arterial blood gases thereby facilitating muscle oxygen availability. 39 The study has several limitations that need to be addressed. First, patients were not blinded to the intervention as there is no convincing way of blinding subjects to NIV. Although other studies have proposed a 'sham' NIV using low levels of pressure support, our experience is that subjects of this disease severity perform poorly when using such conditions, and if they are familiar with an appropriate NIV treatment. Second, all of our patients received supplemental oxygen during exercise which may have interfered with measures of muscle oxygen availability. Additionally, a Figure 3 Transcutaneously measured partial pressure of carbon dioxide (TcPCO 2 ) during cycling constant work rate tests (20-100% of isotime and 6-min post exercise (=recovery)) with supplemental oxygen alone ( ) or in combination with highpressure non-invasive ventilation (NIV) ( ). Data are presented as mean AE SEM (***P < 0.001). direct measurement of the fraction of inspired oxygen (FiO 2 ) was not performed in the current study; therefore, a different amount of oxygen application could have resulted in different outcomes. A former study found distinctly higher changes in leg muscle oxygenation by using NIV in non-hypoxaemic COPD patients without supplemental oxygen. 9 Finally, the present study was performed in a highly selected group with very severe disease who were very familiar with NIV in the APCV mode with high inspiratory pressures, which may affect the generalizability of the results. However, methodological strengths of this study are mentioned in Appendix S3 (Supplementary Information).
Vastus lateralis
In conclusion, NIV with high inspiratory pressure levels during cycling significantly improves exercise performance, exercise-induced hypercapnia and exertional dyspnoea in COPD patients with CHRF. These findings are related to a single bout of exercise and future research would need to investigate these benefits during long-term training programmes.
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